BAUDETTE, Minn., April 27, 2016 /PRNewswire/ -- ANI
Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the
appointment of Stephen P. Carey to
the position of Vice President and Chief Financial Officer,
effective May 6, 2016.
Stephen P. Carey is an
accomplished financial executive with over 20 years of experience,
15 of which are in the pharmaceutical industry. Steve has
held various financial and accounting positions with Schering
Plough Corporation and most recently, Par Pharmaceutical Companies,
Inc., where he was the Senior Vice President, Controller and
Principal Accounting Officer. Steve began his career at
PricewaterhouseCoopers.
Arthur S. Przybyl, President and
Chief Executive Officer, said, "ANI's Board of Directors and I are
excited to introduce Steve as our new CFO. Steve's knowledge
and career experience in the generic pharmaceutical business will
serve to help ANI to continue to grow and create value for our
shareholders. We look forward to introducing Steve to all our
constituents in the near future."
Steve replaces our current CFO, Charlotte C. Arnold, who has been with ANI in
that capacity since 2009. Ms. Arnold will remain as a
consultant to the Company through March
2017.
Mr. Przybyl noted, "When I joined ANI in 2009, Charlotte was the
first executive I hired. Throughout her tenure she has been a
valuable member of the senior management team and played a key role
in the Company's turnaround in 2009 and 2010. She was
instrumental in ANI becoming a public company in 2013 and in
subsequently helping ANI raise over $200
million in capital. She helped transform ANI from a
private to a public company and has built an outstanding finance
and accounting organization to support our rapid organic growth and
business development activities. She has been an important
contributor to the success ANI enjoys today and the Board of
Directors joins me in offering our sincere thanks to Charlotte for
her efforts."
Ms. Arnold stated, "It has been my privilege to work with Art
and the outstanding management team he has assembled at ANI. These
last seven years have been, without a doubt, the most rewarding of
my professional career and I am looking forward to witnessing ANI's
continued growth and success in the years to come."
About ANI
ANI Pharmaceuticals, Inc. (the "Company" or "ANI") is an
integrated specialty pharmaceutical company developing,
manufacturing, and marketing branded and generic prescription
pharmaceuticals. The Company's targeted areas of product
development currently include narcotics, oncolytics (anti-cancers),
hormones and steroids, and complex formulations involving extended
release and combination products. For more information, please
visit our website anipharmaceuticals.com.
Forward-Looking Statements
To the extent any statements made in this release deal with
information that is not historical, these are forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995. Such statements include, but are not limited
to, statements about price increases, the Company's future
operations, products financial position, operating results and
prospects , the Company's pipeline or potential markets therefor,
and other statements that are not historical in nature,
particularly those that utilize terminology such as "anticipates,"
"will," "expects," "plans," "potential," "future," "believes,"
"intends," "continue," other words of similar meaning, derivations
of such words and the use of future dates.
Uncertainties and risks may cause the Company's actual results
to be materially different than those expressed in or implied by
such forward-looking statements. Uncertainties and risks include,
but are not limited to, the risk that the Company may face with
respect to importing raw materials; increased competition;
acquisitions; contract manufacturing arrangements; delays or
failure in obtaining product approval from the U.S. Food and Drug
Administration; general business and economic conditions; market
trends; products development; regulatory and other approvals and
marketing.
More detailed information on these and additional factors that
could affect the Company's actual results are described in the
Company's filings with the Securities and Exchange Commission,
including its most recent annual report on Form 10-K and quarterly
reports on Form 10-Q, as well as its proxy statement. All
forward-looking statements in this news release speak only as of
the date of this news release and are based on the Company's
current beliefs, assumptions, and expectations. The Company
undertakes no obligation to update or revise any forward-looking
statement, whether as a result of new information, future events or
otherwise.
For more information about ANI, please contact:
Investor Relations
IR@anipharmaceuticals.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/ani-announces-appointment-of-stephen-p-carey-as-vice-president-and-chief-financial-officer-300258154.html
SOURCE ANI Pharmaceuticals, Inc.